---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-050756"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T02:15:26.552087+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Oruka Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay

## Summary
- Elected Carl Dambkowski (26,047,914 for) and Peter Harwin (25,935,823 for) as Class I directors.
- Ratified PricewaterhouseCoopers as independent auditor for FY 2025 (26,781,030 for, 1,848 against).
- Non-binding advisory vote approved named executive officer compensation (25,824,834 for, 88,740 against).
- Non-binding vote favored annual frequency for future say-on-pay; board adopted annual frequency.
- All proposals passed; broker non-votes of 732,854 on director and compensation proposals.

## SEC filing metadata
- accession: 0001213900-25-050756
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390025050756/0001213900-25-050756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390025050756/ea0244429-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-050756
- JSON: https://secwatch.observer/filing/0001213900-25-050756.json
- Plain text: https://secwatch.observer/filing/0001213900-25-050756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.